These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Herrera B; van Dinther M; Ten Dijke P; Inman GJ Cancer Res; 2009 Dec; 69(24):9254-62. PubMed ID: 19996292 [TBL] [Abstract][Full Text] [Related]
10. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. van Meeteren LA; Thorikay M; Bergqvist S; Pardali E; Stampino CG; Hu-Lowe D; Goumans MJ; ten Dijke P J Biol Chem; 2012 May; 287(22):18551-61. PubMed ID: 22493445 [TBL] [Abstract][Full Text] [Related]
11. A heterodimer formed by bone morphogenetic protein 9 (BMP9) and BMP10 provides most BMP biological activity in plasma. Tillet E; Ouarné M; Desroches-Castan A; Mallet C; Subileau M; Didier R; Lioutsko A; Belthier G; Feige JJ; Bailly S J Biol Chem; 2018 Jul; 293(28):10963-10974. PubMed ID: 29789425 [TBL] [Abstract][Full Text] [Related]
12. Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors. Breen MJ; Moran DM; Liu W; Huang X; Vary CP; Bergan RC PLoS One; 2013; 8(8):e72407. PubMed ID: 23967299 [TBL] [Abstract][Full Text] [Related]
13. Regulation of the ALK1 ligands, BMP9 and BMP10. Li W; Salmon RM; Jiang H; Morrell NW Biochem Soc Trans; 2016 Aug; 44(4):1135-41. PubMed ID: 27528761 [TBL] [Abstract][Full Text] [Related]
14. Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-α-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2. Mitrofan CG; Appleby SL; Nash GB; Mallat Z; Chilvers ER; Upton PD; Morrell NW J Biol Chem; 2017 Aug; 292(33):13714-13726. PubMed ID: 28646109 [TBL] [Abstract][Full Text] [Related]
15. A Bone Morphogenetic Protein (BMP)-derived Peptide Based on the Type I Receptor-binding Site Modifies Cell-type Dependent BMP Signalling. Tong Z; Guo J; Glen RC; Morrell NW; Li W Sci Rep; 2019 Sep; 9(1):13446. PubMed ID: 31530856 [TBL] [Abstract][Full Text] [Related]
16. Homeobox D3, A Novel Link Between Bone Morphogenetic Protein 9 and Transforming Growth Factor Beta 1 Signaling. Wang L; Yao J; Yu T; Zhang D; Qiao X; Yao Z; Wu X; Zhang L; Boström KI; Yao Y J Mol Biol; 2020 Mar; 432(7):2030-2041. PubMed ID: 32061928 [TBL] [Abstract][Full Text] [Related]
17. Structure of the Alk1 extracellular domain and characterization of its bone morphogenetic protein (BMP) binding properties. Mahlawat P; Ilangovan U; Biswas T; Sun LZ; Hinck AP Biochemistry; 2012 Aug; 51(32):6328-41. PubMed ID: 22799562 [TBL] [Abstract][Full Text] [Related]
18. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. Cunha SI; Pardali E; Thorikay M; Anderberg C; Hawinkels L; Goumans MJ; Seehra J; Heldin CH; ten Dijke P; Pietras K J Exp Med; 2010 Jan; 207(1):85-100. PubMed ID: 20065063 [TBL] [Abstract][Full Text] [Related]
19. Structural Basis of the Human Endoglin-BMP9 Interaction: Insights into BMP Signaling and HHT1. Saito T; Bokhove M; Croci R; Zamora-Caballero S; Han L; Letarte M; de Sanctis D; Jovine L Cell Rep; 2017 May; 19(9):1917-1928. PubMed ID: 28564608 [TBL] [Abstract][Full Text] [Related]
20. Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding. Aykul S; Martinez-Hackert E J Biol Chem; 2016 May; 291(20):10792-804. PubMed ID: 26961869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]